UnknownNot Applicable

Dopamine D2 Receptors(D2R) Imaging in Prolactinomas

50 participantsStarted 2018-12-01

Plain-language summary

To study the in vivo expression of dopamine D2 receptors in prolactinoma and the predictive role of dopamine D2 receptors PET-MR imaging in the therapeutic effect of dopamine agonists.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Hyperprolactinemia;
✓. Enhanced pituitary MRI shows sella regional tumor;
✓. Aged between 18 and 65 years old, either sex;
✓. Karnofsky performance status ≥ 70;
✓. The patient has signed the informed consent.

Exclusion criteria

✕. Patients concomitantly taking the psychotropic drugs or other drugs causing elevated PRL ;
✕. Patients with parkinson disease and is taking dopaminergic agents;
✕. Patients with prolactinoma who received Gamma knife treatment;
✕. Pregnant or lactating women, or women preparing pregnant;
✕. Patients with poor compliance, who cannot implement the program strictly.
✕. History of allergic reactions attributed to compounds of similar chemical or biologic composition to cabergoline.
✕. Patients with claustrophobia

What they're measuring

Change from baseline on PRL level

Timeframe: Up to 6 months

Trial details

NCT IDNCT03717454

SponsorZhebao Wu

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-12-30

Contact for this trial

Weiting Gu, MD

0086-13917778956 nowaiting1221@hotmail.com

View on ClinicalTrials.gov More Prolactinoma trials